SecBot SecBot
PRESS-RELEASE ·Filed Mar 8, 2026

DNTH

Dianthus Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonimmediate Processed8mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

Traders should monitor the March 9 webcast for interim efficacy and safety signals from the Phase 3 trial; positive data could catalyze significant upside given the high unmet need in CIDP and DNTH's $2.8B market cap.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$79.23
T+0 close · Mar 8, 2026 · via day close
Latest settled
+2.95%
T+60 · $81.57
Vs SPY
−9.03%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 9 $79.23entry
  2. T+1 · 8mo ago +9.71%α +9.89% · $86.92
  3. T+5 · 8mo ago −1.55%α −0.20% · $78.00
  4. T+20 · 7mo ago +8.80%α +11.60% · $86.20
  5. T+60 · 6mo ago +2.95%α −9.03% · $81.57
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dianthus Therapeutics announced a conference call to discuss interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in CIDP, scheduled for March 9, 2026. The event is material as it pertains to a key clinical milestone for a Phase 3 program in a severe autoimmune disease, but no results have been disclosed yet.

Key Facts

  • Company to discuss interim responder analysis from Part A of the Phase 3 CAPTIVATE trial of claseprubart in CIDP.
  • Data discussion scheduled for March 9, 2026, at 8:00 a.m. ET via webcast and conference call.
  • No clinical results are released in this announcement, only logistical details for an upcoming event.
  • Claseprubart is being evaluated for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a rare and severe autoimmune neurological disorder.

Financial Impact

Potential high impact pending data release, but no financial figures disclosed in this announcement.

revenuevaluationcash runway

Risk Factors

  • Interim data may show suboptimal response rates or safety concerns, leading to downside risk.
  • Responder analysis is not a primary endpoint and may not predict final trial success.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3251470

Track record

23 reports on DNTH

Performance horizon

7 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +41.40% at T+60 after the Jun 11, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $89.76 Now $89.55 −0.23% settles Nov 17
  2. Nov 9, 20267d ago 144 Neutral 3/10 Entry $88.81 to $89.30 Now $89.55 +0.83% ▲ +0.55% −0.77% vs SPY
  3. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  4. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $83.01 to $86.03 Now $89.55 +7.88% ▲ +3.64% +3.33% vs SPY
  5. Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
  6. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
  7. Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $81.57 to $77.58 Now $89.55 +9.78% ▼ −4.89% −4.88% vs SPY
  8. Aug 11, 202613w ago Insider Cluster Neutral 4/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
  9. Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
  10. Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (11h 11m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 8, 2026